Nicholas Schwab

Human myoblasts modulate the function of antigen-presenting cells.

The cognitive and affective dimensions of moral conviction: implications for attitudinal and behavioral measures of interpersonal tolerance.

The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy.

CD8+ T-cell clones dominate brain infiltrates in Rasmussen encephalitis and persist in the periphery.

PD-1 regulates neural damage in oligodendroglia-induced inflammation.

Intercellular exchanges of membrane fragments (trogocytosis) between human muscle cells and immune cells: a potential mechanism for the modulation of muscular immune responses.

T cell suppression by naturally occurring HLA-G-expressing regulatory CD4+ T cells is IL-10-dependent and reversible.

Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants.

Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation.

An imbalance of two functionally and phenotypically different subsets of plasmacytoid dendritic cells characterizes the dysfunctional immune regulation in multiple sclerosis.

FOXP3+ T regulatory cells in idiopathic inflammatory myopathies.

Temporal pattern of ICAM-I mediated regulatory T cell recruitment to sites of inflammation in adoptive transfer model of multiple sclerosis.

Janus head: the dual role of HLA-G in CNS immunity.

Regulatory T cells exhibit enhanced migratory characteristics, a feature impaired in patients with multiple sclerosis.

Immunological and clinical consequences of treating a patient with natalizumab.

L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients.

CD4+NKG2D+ T cells exhibit enhanced migratory and encephalitogenic properties in neuroinflammation.

Specific loss of cellular L-selectin on CD4+ T cells is associated with PML development during HIV infection.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.

Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Trafficking of lymphocytes into the CNS.

PML risk stratification using anti-JCV antibody index and L-selectin.

Clustering of worry appraisals among college students.

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values.

CD8(+) T-cell pathogenicity in Rasmussen encephalitis elucidated by large-scale T-cell receptor sequencing.

Impaired NK-mediated regulation of T-cell activity in multiple sclerosis is reconstituted by IL-2 receptor modulation.

Distinct pattern of lesion distribution in multiple sclerosis is associated with different circulating T-helper and helper-like innate lymphoid cell subsets.

CD62L is not a reliable biomarker for predicting PML risk in natalizumab-treated R-MS patients.

B7-H1 shapes T-cell-mediated brain endothelial cell dysfunction and regional encephalitogenicity in spontaneous CNS autoimmunity.

Melanocortin-1 receptor activation is neuroprotective in mouse models of neuroinflammatory disease.

CD62L test at 2 years of natalizumab predicts progressive multifocal leukoencephalopathy.

Natalizumab-associated PML: Challenges with incidence, resulting risk, and risk stratification.